TLCD3A

Across TCGA pan-cancer cohorts, TLCD3A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TLCD3A data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TLCD3A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TLCD3A expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where TLCD3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	1.000	0.589	.013	11	view →
LSCC	DFS	Median	III,IV	0.984	0.508	.010	9	view →
CCRCC	DFS	Median	All	1.000	0.701	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TLCD3A–LUAD (DFS)

Open the LUAD breakdown →